• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Gilead, Foresite back biotech developer of COVID-19 pill in latest SPAC deal

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jun 30, 2021 at 12:12: AM
via A little-known biotech company developing an antiviral pill for COVID-19 is going public through a merger with a blank-check company launched by the venture firm Foresite Capital, a deal that will hand the California-based developer $276 million to advance its drug candidate into clinical testing.

article source
 




Top Bottom
Back
Quote